Can Serum Lumican Level Identify a Hidden Fragility Phenotype Beyond Bone Mineral Density in Postmenopausal Women?
Recruiting now
Conditions studied: Osteoporosis, Postmenopausal Osteoporosis, Frailty, Fragility Fractures
In brief
Osteoporosis is a major cause of morbidity and fragility fractures in postmenopausal women. Bone mineral density (BMD) alone may not fully reflect fracture risk and skeletal fragility. Lumican, an extracellular matrix proteoglycan involved in collagen organization and musculoskeletal tissue homeostasis, has emerged as a potential biomarker for bone health. This prospective observational study aims to investigate the relationship between serum lumican levels, bone mineral density, muscle strength, and clinical fragility indicators in postmenopausal women. Approximately 100 participants will undergo routine osteoporosis assessment including DEXA, laboratory testing, FRAX evaluation, and handgrip strength measurement. The study will evaluate whether serum lumican levels can identify a hidden fragility phenotype beyond conventional bone mineral density measurements.
Key facts
- Study ID
- NCT07677072
- Run by
- Kanuni Sultan Suleyman Training and Research Hospital
- People needed
- 98
- Starts
- 2026-05-15
- Expected to finish
- 2026-12-01
- Last updated by the study team
- 2026-06-30
Who can join
Age: 45 and older. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Inclusion Criteria:
- Female sex
- Age 45 years or older
- Postmenopausal status
- Attendance at the Physical Medicine and Rehabilitation outpatient clinic
- Undergoing routine bone mineral density (DEXA) assessment and osteoporosis laboratory evaluation
- Ability and willingness to provide written informed consent
You may not qualify if…
- Exclusion Criteria:
- Premenopausal women
- Secondary causes of osteoporosis (e.g., malignancy, advanced renal failure, severe liver disease, significant endocrine disorders)
- Active infection or acute inflammatory disease
- Major surgery within the previous 6 months
- Neurological or muscular disorders that may significantly affect muscle function
- Inability to comply with study procedures and assessments
- Current treatment with medications that significantly affect bone metabolism, including bisphosphonates, denosumab, teriparatide, or other anti-osteoporotic agents
- Refusal or inability to provide written informed consent
Where it is running
- Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey — Küçükçekmece, Istanbul, Turkey (Türkiye) (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.